Kepler Cheuvreux on Wednesday upgraded Danish biotechnology company Novonesis (NSIS-B.CO) to buy from hold and raised its price target to 460.00 Danish kroner from 390.00 kroner.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:POW reported strong Q1 2026 adjusted EPS of CAD1.43 vs. CAD1.22 a year ago, reflecting broad-based strength across most operating segments and matching our CAD1.42 estimate and the CAD1.43 consensus view. Net earnings from continuing operations rose 19% to CAD820M, while EPS increased nearly 21% to CAD1.29 vs. CAD1.07 in the prior-year period, demonstrating solid operational execution. The results highlight POW's ability to deliver consistent performance across its diversified portfolio of operating companies. Net EPS growth exceeded 20%, underscoring the company's strong earnings momentum and effective capital allocation strategies. The robust performance across most business segments reflects the resilience of POW's operating model and the underlying strength of its key subsidiaries. These solid Q1 results position POW favorably as it continues to execute on strategic initiatives and optimize value creation across its portfolio companies.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:FNV reported Q1 adjusted EPS of $2.38 vs. $1.07 prior year, $0.30 above consensus, with record revenue of $650.7M (+77% Y/Y) driven by gold averaging $4,875/oz (+70% Y/Y) and silver at $84.39/oz (+165% Y/Y). Adjusted EBITDA margins expanded to 91.0% from 87.4%, generating record adjusted EBITDA of $591.9M (+84% Y/Y). We believe FNV's capital-light model provides superior leverage to commodity prices while avoiding operational risks including cost inflation and technical challenges. Management maintained 2026 guidance of 510,000-570,000 GEOs, with ~90% from precious metals. Recent acquisitions totaling ~$515M, including i-80 Gold ($250M) and Casa Berardi ($100M), enhance growth while maintaining the debt-free balance sheet with $3.4B available capacity. Panama's authorization to process Cobre Panama stockpiled ore provides optionality, with potential for 150,000-175,000 annual GEOs if full restart occurs, though timing remains uncertain.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CSU delivered strong Q1 results, with revenue of $3.18B (+20% Y/Y), beating consensus by $40M, driven primarily by acquisitions with organic growth of 6% (2% FX-adjusted). Net income surged 170% to $367M ($17.32 EPS) versus $136M ($6.41 EPS) in the prior year, well above consensus of $9.95, benefiting from revenue growth, operational leverage, and favorable non-operating items including a $76M IRGA/TSS membership liability revaluation gain. The company continued executing its acquisition-driven growth strategy, deploying $809M in Q1, with an additional $786M committed post-quarter. The recurring revenue model demonstrated strength, with maintenance and other recurring revenue growing 22% to $2.44B, representing 77% of total revenue. Free cash flow available to shareholders jumped 44% to $733M, reflecting improved working capital management and operating leverage, while the balance sheet remained solid, with $3.01B in cash.